Julie Brown - GlaxoSmithKline Plc Chief Officer
| GSKN Stock | MXN 739.40 0.57 0.08% |
Insider
Julie Brown is Chief Officer of GlaxoSmithKline plc
| Age | 61 |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GlaxoSmithKline Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GlaxoSmithKline Plc's management efficiency ratios could be used to measure how well GlaxoSmithKline Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Luis Morales | GMxico Transportes SAB | N/A | |
| Mauricio Campos | GMxico Transportes SAB | 50 | |
| Fernando Sahagun | GMxico Transportes SAB | 76 | |
| Emilio Gamboa | GMxico Transportes SAB | 85 | |
| Kazutoshi Kuwahara | Genworth Financial | N/A | |
| Brian Haendiges | Genworth Financial | 62 | |
| Claudio Laporte | GMxico Transportes SAB | N/A | |
| Tamara Erwin | Verizon Communications | 58 | |
| Gregory Karawan | Genworth Financial | 58 | |
| John II | Genworth Financial | N/A | |
| Samantha Hammock | Verizon Communications | 44 | |
| Vandana Venkatesh | Verizon Communications | N/A | |
| Antonio Ruiz | GMxico Transportes SAB | 81 | |
| Robert Axel | Prudential Financial | N/A | |
| James Gerace | Verizon Communications | 59 | |
| Rafael Garcia | GMxico Transportes SAB | N/A | |
| CFA IV | Genworth Financial | 57 | |
| Isaac Unkind | GMxico Transportes SAB | N/A | |
| Prudencio Martinez | GMxico Transportes SAB | N/A | |
| Carlos Sierra | GMxico Transportes SAB | N/A | |
| Lee Augsburger | Prudential Financial | 63 | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 |
GlaxoSmithKline plc Leadership Team
Elected by the shareholders, the GlaxoSmithKline Plc's board of directors comprises two types of representatives: GlaxoSmithKline Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline Plc's management team and ensure that shareholders' interests are well served. GlaxoSmithKline Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Redfern, Chief Strategy Officer | ||
| Diana Conrad, Chief Officer | ||
| Emma Walmsley, President - Consumer Healthcare Worldwide | ||
| Sally Jackson, VP Office | ||
| Iain Mackay, CFO - Designate, Executive Director | ||
| James Ford, Sr Compliance | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Julie Brown, Chief Officer | ||
| Tony Wood, Chief Officer |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 1.79 T | |||
| Shares Outstanding | 2.05 B | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 14.10 % | |||
| Price To Earning | 11.33 X | |||
| Price To Book | 6.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for GlaxoSmithKline Stock Analysis
When running GlaxoSmithKline Plc's price analysis, check to measure GlaxoSmithKline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline Plc is operating at the current time. Most of GlaxoSmithKline Plc's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline Plc's price. Additionally, you may evaluate how the addition of GlaxoSmithKline Plc to your portfolios can decrease your overall portfolio volatility.